title: Noninvasive prenatal testing in China: Future detection of rare genetic diseases?
abstract: Noninvasive prenatal testing (NIPT) provides an innovative method to detect genetic conditions in fetuses using a maternal blood sample, thus avoiding the risk of miscarriage associated with traditional invasive procedures. Since 80% of rare diseases are genetic diseases, NIPT has the potential to detect rare genetic diseases early on and it has been used in many countries and regions. Since China has the world's largest population of patients with rare diseases, NIPT has been implemented in China since 2010. However, the regulations governing NIPT in China are weak and NIPT oversight and research are still lacking. Strict registration is needed to ensure the quality of NIPT, additional certification can help a developer/manufacturer of an NIPT test to compile clinical data and to improve innovation, and academic societies can provide committee opinions that are suited to the current situation in China. These efforts may improve regulations governing NIPT and NIPT oversight and research in China. With these improvements, NIPT may offer promise in terms of the early detection of rare diseases.
authors.affiliation: Department of Health Care Management and Maternal and Child Health, Shandong University, Ji'nan, Shandong, China; ; School of Stomatology, Shandong University, Ji'nan, Shandong, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Mei
authors.affiliation: Department of Health Care Management and Maternal and Child Health, Shandong University, Ji'nan, Shandong, China;
authors.forename: Qi
authors.initials: Q
authors.lastname: Tang
authors.affiliation: School of Stomatology, Shandong University, Ji'nan, Shandong, China.
authors.forename: Baiyu
authors.initials: B
authors.lastname: Sun
authors.affiliation: Department of Health Care Management and Maternal and Child Health, Shandong University, Ji'nan, Shandong, China;
authors.forename: Lingzhong
authors.initials: L
authors.lastname: Xu
keywords: Clinical Laboratory Improvement Amendments (CLIA); Committee opinion; Laboratory Developed Tests (LDTs); Premarket notification